- $17.06m
- $71.76m
- $2.45m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.5 | 0.377 | 2.45 |
Cost of Revenue | |||||
Gross Profit | — | — | -0.085 | -3.24 | -3.97 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 16.1 | 29.8 | 58.3 | 96.7 | 75 |
Operating Profit | -16.1 | -29.8 | -57.8 | -96.4 | -72.6 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17.3 | -35.9 | -56.1 | -103 | -79.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -17.3 | -35.9 | -56.1 | -103 | -79.3 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -16.5 | -34.3 | -50.3 | -89 | -64.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -16.7 | -34.6 | -50.6 | -89.3 | -66.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.4 | -8.88 | -9.14 | -14.1 | -8.78 |